Metraipolis › archive › dc_42025624ea98

Neoadjuvant serplulimab and SOX chemotherapy for locally advanced gastric cancer: pathological responses and systemic immune signatures from a phase II trial — Europe PMC PMID:41601630

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41601630
DOI
10.3389/fimmu.2025.1702737
License (as archived)
solo-consultazione
Archived
2026-11-06T21:30:38.467Z
SHA-256 of the archived text
9f9fd98f1ba40759163ccd179dd142d9b962e0823bb30900121e2e0e02b4da09
Stable URL of this page
https://metraipolis.com/documento/dc_42025624ea98

How to cite

Neoadjuvant serplulimab and SOX chemotherapy for locally advanced gastric cancer: pathological responses and systemic immune signatures from a phase II trial — Europe PMC PMID:41601630 — Europe PMC (en), https://europepmc.org/article/MED/41601630 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_42025624ea98 (Metraipolis archive dc_42025624ea98, sha256 9f9fd98f1ba40759163ccd179dd142d9b962e0823bb30900121e2e0e02b4da09)
BibTeX
@misc{dc42025624ea98,
  title = {Neoadjuvant serplulimab and SOX chemotherapy for locally advanced gastric cancer: pathological responses and systemic immune signatures from a phase II trial — Europe PMC PMID:41601630},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41601630},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_42025624ea98; sha256 9f9fd98f1ba40759163ccd179dd142d9b962e0823bb30900121e2e0e02b4da09},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41601630. Agents can read the archived copy with the MCP tool read_document.